MY210039A - Compounds, compositions, and methods for modulating cdk9 activity - Google Patents

Compounds, compositions, and methods for modulating cdk9 activity

Info

Publication number
MY210039A
MY210039A MYPI2021002367A MYPI2021002367A MY210039A MY 210039 A MY210039 A MY 210039A MY PI2021002367 A MYPI2021002367 A MY PI2021002367A MY PI2021002367 A MYPI2021002367 A MY PI2021002367A MY 210039 A MY210039 A MY 210039A
Authority
MY
Malaysia
Prior art keywords
modulating
compositions
compounds
methods
cdk9 activity
Prior art date
Application number
MYPI2021002367A
Other languages
English (en)
Inventor
Andrew Tasker
David Freeman
Joseph VACCA
Peter Mikochik
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of MY210039A publication Critical patent/MY210039A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2021002367A 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity MY210039A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
MY210039A true MY210039A (en) 2025-08-22

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021002367A MY210039A (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Country Status (21)

Country Link
US (3) US11155560B2 (https=)
EP (1) EP3873911A4 (https=)
JP (1) JP7385658B2 (https=)
KR (2) KR20250174699A (https=)
CN (1) CN112996790B (https=)
AU (1) AU2019370200B2 (https=)
BR (1) BR112021008176A2 (https=)
CA (1) CA3118472A1 (https=)
CO (1) CO2021005502A2 (https=)
CR (1) CR20210202A (https=)
DO (1) DOP2021000066A (https=)
IL (1) IL282254B2 (https=)
MA (1) MA54092A (https=)
MD (1) MD20210033A2 (https=)
MX (1) MX2021004769A (https=)
MY (1) MY210039A (https=)
PE (1) PE20212196A1 (https=)
PH (1) PH12021550857A1 (https=)
SG (1) SG11202104229WA (https=)
WO (1) WO2020092314A1 (https=)
ZA (1) ZA202102609B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP7814386B2 (ja) * 2020-11-05 2026-02-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
EP4282868B1 (en) * 2021-01-22 2026-03-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
JP2024543136A (ja) * 2021-11-24 2024-11-19 クロノス バイオ インコーポレイテッド （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態
JP2025527161A (ja) * 2022-07-22 2025-08-20 上海海雁醫藥科技有限公司 置換されたピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体の薬学的に許容される塩および多形体、ならびにその使用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
WO1995035298A1 (en) 1994-06-21 1995-12-28 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
CA2379585C (en) 1999-09-30 2006-06-20 James W. Darrow Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MXPA05002571A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
WO2006016715A1 (ja) * 2004-08-13 2006-02-16 Teijin Pharma Limited ピラゾロ［１，５－ａ］ピリミジン誘導体
CA2591125A1 (en) 2004-12-21 2006-06-29 Schering Corporation Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2007139732A1 (en) 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
AU2008261027A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
CN101784276A (zh) 2007-06-27 2010-07-21 传染性疾病研究院 化合物在用于制备抗结核药剂中的用途
US20110201599A1 (en) * 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
MY183861A (en) 2010-03-05 2021-03-17 Kyowa Hakko Kirin Co Ltd Pyrazolopyrimidine derivative
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013104611A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3125907A4 (en) 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
USRE50776E1 (en) * 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3356330B1 (en) 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US11112410B2 (en) 2016-04-13 2021-09-07 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
US20190060296A1 (en) * 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Also Published As

Publication number Publication date
CN112996790A (zh) 2021-06-18
AU2019370200B2 (en) 2024-12-19
ZA202102609B (en) 2023-02-22
AU2019370200A1 (en) 2021-06-10
MA54092A (fr) 2021-09-08
MX2021004769A (es) 2021-08-24
KR20210068597A (ko) 2021-06-09
MD20210033A2 (ro) 2021-10-31
US11155560B2 (en) 2021-10-26
PE20212196A1 (es) 2021-11-16
IL282254A (en) 2021-05-31
KR20250174699A (ko) 2025-12-12
US20200131189A1 (en) 2020-04-30
US20240132506A1 (en) 2024-04-25
US11845754B2 (en) 2023-12-19
CA3118472A1 (en) 2020-05-07
US20220002305A1 (en) 2022-01-06
DOP2021000066A (es) 2021-10-31
JP7385658B2 (ja) 2023-11-22
WO2020092314A1 (en) 2020-05-07
CN112996790B (zh) 2023-11-03
EP3873911A1 (en) 2021-09-08
PH12021550857A1 (en) 2021-12-06
EP3873911A4 (en) 2022-06-22
IL282254B2 (en) 2025-08-01
JP2022505268A (ja) 2022-01-14
IL282254B1 (en) 2025-04-01
CO2021005502A2 (es) 2021-09-20
SG11202104229WA (en) 2021-05-28
BR112021008176A2 (pt) 2021-08-03
CR20210202A (es) 2022-02-08

Similar Documents

Publication Publication Date Title
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
EA201690752A1 (ru) Ингибиторы g12c kras
PH12021550019A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
EA201991884A3 (ru) Ингибиторы g12c kras
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2022008103A (es) Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
PH12017502407B1 (en) Fused pyrimidine compound or salt thereof
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.